Researchers from Terasaki Institute for Biomedical Innovation (“TIBI”) have designed a microneedle patch that will be used to deliver drugs and is currently being modified for use in micro-dosing psychedelic substances. These compounds include psilocybin mushrooms, LSD and MDMA, all of which have the potential to treat severe pain as well as mental health conditions such as depression and anxiety.
The microneedle patch, GeIMA, has been developed using a gelatinous substance, and its surface is made up of tiny microneedles that would contain the drug or drugs to be administered to an individual. When the patch is applied to the skin, its microneedles pierce the epidermis then biodegrade, thus allowing it to release the medicine in a manner that can be adapted for timed release and dosage.
The researchers’ original patch had been designed for various uses, which included gene and stem cell therapies and drug delivery. Presently, however, the team from TIBI is now collaborating with PharmaTher Inc. to design a microneedle patch that will be used to deliver psychedelic medicines for various medical needs.
PharmaTher is engaged in the research and development of psychedelic medicines and has partnered with TIBI to design the patches, which will be used with PharmTher products as an alternative way to administer treatment.
While there are those who are still of the opinion that psychedelic drugs are harmful and dangerous, recent clinical trials and experiments conducted to evaluate the potential medical benefits that various psychedelics possess have achieved positive results. Thus far, researchers have seen successful results when using psychedelics to treat various conditions, including smoking addiction, alcohol addiction and even post-traumatic stress disorder. In general, these psychedelic treatments have also been beneficial for individuals who had tried to manage their conditions using other treatments but had found no success.
PharmaTher CEO Fabio Chianelli stated that the company was excited to be collaborating with the Terasaki Institute on the GeIMA delivery technology project, adding that it provided the company with a solid basis to advance the product as well as the clinical development of a novel microdosing delivery system, which would provide a solution to a previously unmet need.
Chianelli added that PharmaTher was focused on developing prescription-based psychedelic medicines for international regulatory approval as well as approval from the U.S. Food and Drug Administration. The microneedle patch designed by TIBI researchers, he said, would help unlock the potential therapeutic value of psychedelic compounds.
Recent research is continuing to reveal the immense potential that psychedelics have in the treatment of mental health conditions, and this new dawn augers well for Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF), which has added a functional mushrooms vertical to its already successful operations in the cannabis extracts sector.
NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) are available in the company’s newsroom at https://ibn.fm/PULL
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
